A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Lazertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Acronyms LASER201
- Sponsors Janssen Research & Development; Yuhan
Most Recent Events
- 21 Mar 2025 Status changed from active, no longer recruiting to completed.
- 01 Apr 2024 Results from long term follow up published in the Lung Cancer
- 24 Oct 2023 Results (n=332) of an integrated analysis characterizing clinical features of paresthesia and related AEs, and examined effect of lazertinib dose reduction (DR) on drug exposure, safety and clinical efficacy presented at the 48th European Society for Medical Oncology Congress